RCC Outcomes Optimization

CE / CME

Optimizing Outcomes for Patients With RCC

Pharmacists: 1.00 contact hour (0.1 CEUs)

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: April 07, 2023

Expiration: April 06, 2024

Katy Beckermann
Katy Beckermann, MD, PhD

Activity

Progress
1
Course Completed
Introduction

In this module, Katy Beckermann, MD, PhD, discusses current information on the treatment of advanced clear cell renal cell carcinoma (RCC).

Please note that the key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be downloaded here or by clicking on any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options (CCO) plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

 

Before continuing with this educational activity, please take a moment to answer the following questions

Which of the following best describes your role on the oncology care team?

Which best describes your practice setting?

For those providing patient care, how many patients with RCC do you provide care for in a typical month?

All of the following factors are important to consider when deciding on first-line treatment recommendations for patients with metastatic RCC EXCEPT which one?

In a consultation for a patient with newly diagnosed metastatic RCC, the patient mentions he has heard about a drug called tivozanib and asks if he would be an appropriate candidate. In your discussion, you tell him that the VEGF TKI tivozanib would be a potential treatment option for him at what point in his disease course?

A 71-year-old man with hypertension, diabetes, and recurrent metastatic clear cell RCC status post right radical nephrectomy is started on axitinib/pembrolizumab. During his first cycle of therapy, he develops grade 2 diarrhea. What would be the most appropriate treatment for this patient?

You are discussing adjuvant therapy for RCC with your fellow in clinic and are reviewing the phase III KEYNOTE-564 study of pembrolizumab vs placebo as adjuvant therapy in clear cell RCC. Which of the following patient populations would you tell her had the largest absolute difference in 24-month disease-free survival (DFS) with pembrolizumab vs placebo?